Hyaluronic acid (HA) is available in a wide range of molecular weights, each offering distinct benefits for skincare formulations. High molecular weight HA (1.0-1.6 MDa) provides surface hydration and plumping, while low molecular weight HA (<10 kDa) penetrates deeper for anti-inflammatory and anti-aging effects. Understanding the MW spectrum is crucial for formulators creating targeted skincare products.
NMN vs NR: Which NAD+ Precursor is Right for Your Supplement?
Both Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR) are effective NAD+ precursors, but they differ in bioavailability, molecular pathways, and clinical evidence. NMN (CAS 1094-61-7) has shown superior bioavailability in recent studies and directly produces NAD+ in one step. This article compares the two and helps supplement manufacturers make informed sourcing decisions.
Quality Certifications in Chemical Supply: What to Look For
When sourcing chemical ingredients for cosmetic, pharmaceutical, or nutraceutical manufacturing, certification verification is critical. This guide covers the essential certifications including cGMP, ISO 9001:2015, FDA registration, Kosher, Halal, REACH compliance, and Non-GMO verification — and what each means for your supply chain quality assurance.
FDA Confirms Combination Product Pathway for RapiGenes Platform
FDA OCP Confirms Combination Product Regulatory Pathway for RapiGenes Autoinjector Platform
RapiGenes announced today that the U.S. Food and Drug Administration Office of Combination Products (OCP) has confirmed the drug-device combination product regulatory pathway for its novel autoinjector platform. This designation enables a streamlined development path under 21 CFR Part 3.2(e).
The OCP determination classifies RapiGenes autoi-njector as a combination product with the Center for Drug Evaluation and Research (CDER) serving as the lead review center. This classification provides clarity on the pre-submission, investigational new drug (IND), and marketing application requirements.
This regulatory milestone validates our platform approach and accelerates our path to IND submission, said Dr. Sarah Chen, CEO of RapiGenes. With the OCP designation confirmed, we can proceed with our IND-enabling studies and pre-IND meeting package.
RapiGenes is currently preparing its pre-RFD (Request for Designation) package and expects to file its IND application in Q3 2025. The company is actively seeking government and commercial partners for co-development of specific drug-device combinations.